Etobicoke, Canada Clinical Trials

A listing of Etobicoke, Canada clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 338 clinical trials
featured
C2541013 MIRNA NASH  

The study aims to evaluate two, orally administered, investigational agents - PF-06865571 (DGAT2 inhibitor) and the coadministration of PF-06865571 with PF-05221304 (ACC inhibitor). This study is specifically designed to evaluate the effect of a range of doses of DGAT2i alone, and DGAT2i + ACCi, on resolution of NASH or improvement …

Toronto Liver Centre
 (5.2 away)
  • 261 views
  • 19 Jul, 2021
  • +64 other locations
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma

Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving radiation with concomitant and adjuvant …

University Health Network-Princess Margaret Hospital
 (6.6 away) Contact site
  • 167 views
  • 25 Jul, 2021
  • +125 other locations
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

This study is evaluating the efficacy of acalabrutinib in combination with bendamustine and rituximab (BR) compared with placebo plus BR in subjects with previously untreated mantle cell lymphoma.

bendamustine
rituximab
cyclin d1
acalabrutinib
Research Site
 (9.7 away) Contact site
  • 1270 views
  • 24 Jul, 2021
  • +250 other locations
A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib versus treatment with physician's choice of abiraterone acetate, enzalutamide, or docetaxel.

Princess Margaret Cancer Centre
 (6.6 away) Contact site
  • 2496 views
  • 24 Jul, 2021
  • +209 other locations
A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant treatment in patients with HR+/HER2- Early Breast Cancer

Novartis Investigative Site
 (9.7 away) Contact site
  • 211 views
  • 17 Jul, 2021
  • +362 other locations
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab Followed by Maintenance Durvalumab Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients

This is a Phase III randomised, double-blind, multi-centre study to evaluate the efficacy and safety of durvalumab in combination with standard of care platinum based chemotherapy and bevacizumab followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian cancer.

Research Site
 (6.6 away) Contact site
  • 84 views
  • 25 Jul, 2021
  • +287 other locations
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

The purpose of this study is to evaluate the efficacy and safety (including evaluating side effects) of combination of olaparib and abiraterone versus placebo and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have received no prior cytotoxic chemotherapy or new hormonal agents (NHAs) at metastatic castration-resistant prostate …

olaparib
ct scan
prostate adenocarcinoma
MRI
adenocarcinoma
Research Site
 (9.7 away) Contact site
  • 200 views
  • 23 Jul, 2021
  • +194 other locations
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC

A Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment and Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer

Research Site
 (6.8 away) Contact site
  • 147 views
  • 14 Jul, 2021
  • +264 other locations
Efficacy Safety and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis.

This clinical study will test the effects of a drug called apremilast in oligoarticular psoriatic arthritis with less than 5 years of disease duration. In previous studies, apremilast has been shown to be safe and efficacious in reducing signs and symptoms of psoriatic arthritis, as well as improving physical function. …

apremilast
Toronto Western Hospital
 (5.8 away) Contact site
  • 265 views
  • 25 Jul, 2021
  • +267 other locations
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

This study will evaluate the efficacy and safety of olaparib (MK-7339) monotherapy in participants with multiple types of advanced cancer (unresectable and/or metastatic) that: 1) have progressed or been intolerant to standard of care therapy; and 2) are positive for homologous recombination repair mutation (HRRm) or homologous recombination deficiency (HRD).

Sunnybrook Health Science Centre ( Site 0210)
 (9.7 away) Contact site
  • 135 views
  • 25 Jul, 2021
  • +146 other locations